GSTM1 and chronic kidney disease: When an ESA is used to treat renal anemia, it can increase the hemoglobin (Hb) level, reduce the need for blood transfusions, and improve quality-of-life, and these drugs have therefore been a key treatment for anemia in patients with CKD since 1989 (Kaplan, 2019).